Apotex Can Pursue $60M Fee In BMS, Aventis Dispute: Court

Law360, New York (November 15, 2012, 7:48 PM EST) -- A New Jersey appellate court on Thursday reversed summary judgment for Sanofi-Aventis and Bristol-Myers Squibb Co. on Apotex Inc.'s claim that it's owed $60 million under a patent litigation settlement, finding that key facts involving that break-up fee remain unresolved.

Apotex was fighting with the drugmakers over their patent for the blood thinner Plavix and its own plans to market a generic version, and was supposed to receive the $60 million fee if the Federal Trade Commission or a consortium of state attorneys general didn't approve...
To view the full article, register now.